<DOC>
	<DOCNO>NCT01610141</DOCNO>
	<brief_summary>The purpose study determine whether pharmacogenetic guide dose warfarin promise improvement efficiency , therapeutic efficacy , , especially , safety warfarin therapy dose regimen without pharmacogenetic information Chinese patient initiate warfarin anticoagulation .</brief_summary>
	<brief_title>Applying Pharmacogenetics Warfarin Dosing Chinese Patients</brief_title>
	<detailed_description>Warfarin widely use oral anticoagulation drug prevent treat thromboembolic event , great 10-fold interindividual variability dose require attain therapeutic response . In 2007 , US Food Drug Administration update label warfarin , recommend consideration pharmacogenetic information confirm contribute significantly variability warfarin dose requirement . Thereafter , multiple pharmacogenetic dosing algorithms construct predict warfarin dose integrate clinical genetic factor . Taken together , approximately one-third one- half variability warfarin dose could explain propose algorithm . However , potential benefit dose algorithm term safety clinical utility adequately investigate randomised setting Chinese patient . Study objectives : 1 . To apply routine pharmacogenetic ( PG ) -guided dose warfarin clinical practice Chinese patient . 2 . To compare percentage out-of-range ( % OOR ) International Normalized Ratios ( INRs ) first 3 month warfarin therapy use PG-guided dose historical standard ( STD ) , empiric dose control . 3 . To compare cost effectiveness , number thromboembolic bleed event , time within therapeutic INR range , time reach stable dose number supratherapeutic INR peak first 3 month warfarin therapy use PG-guided dose historical standard ( STD ) , empiric dose control . Study design : This prospective , randomized study Chinese patient initiate chronic warfarin anticoagulation specific , qualify clinical reason ( i.e. , atrial fibrillation , Deep vein thrombosis/pulmonary embolism , Prosthetic valve replacement ) . Qualifying patient consent randomized individualize , pharmacogenetic guide warfarin-dosing regimen ( PG group ) standard care ( without knowledge genotype ) ( STD group ) . All patient receive baseline INR . For patient PG group , maintenance dose patient predict pharmacogenetic algorithm derive previously Chinese . A maintenance dose 3 mg/day design patient STD group . The start dose warfarin twice assign daily maintenance dose prescribe first second day , dose revert assign maintenance dose . Study duration : Each patient participate least 3 month .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Patients â‰¥18 year old Patients initiated warfarin venous thromboembolism , pulmonary embolism , atrial fibrillation heart valve replacement require long term oral anticoagulation target INR range 1.53.0 least 3 month Ability attend schedule visit Signed informed consent Noneligible subject Pregnant , lactate childbearing potential woman Patients severe comorbidities ( e.g. , renal insufficiency/creatinine &gt; 2.5 mg/dL , hepatic insufficiency , active malignancy , terminal disease ) Known genotype CYP2C9 VKORC1 start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>warfarin metabolism</keyword>
	<keyword>pharmacogenetics</keyword>
	<keyword>CYP2C9</keyword>
	<keyword>genotyping</keyword>
	<keyword>VKORC1</keyword>
	<keyword>CYP4F2</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>atrial fibrillation</keyword>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>Artificial Heart Valve</keyword>
</DOC>